Arthur F Ryan sold $78k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $778.53, traded Feb 9, 2026, filed Feb 11, 2026.
Score components
- +15RoleDirector
- +9Trade size$78k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.1%, 3m -7.5%, 6m +2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001187443-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $775.63 | $776 | 17,902 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -10 | $776.59 | $7,766 | 17,892 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -57 | $777.56 | $44k | 17,835 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -12 | $778.53 | $9,342 | 17,823 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -5 | $779.41 | $3,897 | 17,818 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $780.09 | $780 | 17,817 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -5 | $781.48 | $3,907 | 17,812 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $782.53 | $783 | 17,811 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -3 | $783.34 | $2,350 | 17,808 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $784.59 | $785 | 17,807 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $785.71 | $786 | 17,806 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $786.29 | $1,573 | 17,804 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $787.82 | $788 | 17,803 | Feb 11, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.